Medical Costs Related to Enzyme Replacement Therapy for Mucopolysaccharidosis Types I, II, and VI in Brazil: A Multicenter Study  by Bitencourt, Fernanda Hendges de et al.
Avai lable onl ine at www.sc iencedirect .comV A L U E I N H E A L T H R E G I O N A L I S S U E S 8 C ( 2 0 1 5 ) 9 9 – 1 0 62212-1099$36.00 – s
Published by Elsevie
http://dx.doi.org/10
Conﬂict of intere
E-mail: ischwart
* Address corresp
Ramiro Barcelos 235journal homepage: www.elsevier .com/ locate /vhr iMedical Costs Related to Enzyme Replacement Therapy for
Mucopolysaccharidosis Types I, II, and VI in Brazil:
A Multicenter Study
Fernanda Hendges de Bitencourt1,2, Taiane Alves Vieira, PhD1,3, Carlos Eduardo Steiner, MD, PhD4,
Jordão Correa Neto, MD5, Raquel Boy, MD, PhD6, Ida Vanessa Doederlein Schwartz, MD, PhD7,8,*
1Federal University of Rio Grande do Sul, Porto Alegre, Brazil; 2Health Technology Assessment for Clinical Genetics Group, Federal
University of Rio Grande do Sul, Porto Alegre, Brazil; 3Bioethics Service, Hospital de Clínicas of Porto Alegre, Porto Alegre, Brazil;
4Department of Medical Genetics, University of Campinas, Campinas, Brazil; 5Pontiﬁcal Catholic University of Campinas, Campinas,
Brazil; 6Department of Pediatrics, State University of Rio de Janeiro, Rio de Janeiro, Brazil; 7Medical Genetics Service, Hospital de
Clínicas of Porto Alegre, Porto Alegre, Brazil; 8Department of Genetics, Federal University of Rio Grande do Sul, Porto Alegre, BrazilA B S T R A C TBackground: Mucopolysaccharidosis (MPS) type I (MPS I), MPS type II
(MPS II), and MPS type VI (MPS VI) are lysosomal storage disorders for
which enzyme replacement therapy (ERT) is available. Objective: The
objective of this study was to evaluate the frequency of medical
interventions in a cohort of patients with MPS I, II, and VI on ERT to
estimate the impact of direct medical costs associated with the
treatment of MPS and compare its frequency with that observed
among patients not on ERT. Methods: This was a multicenter study
using a retrospective design including a convenience sampling of
Brazilian patients with MPS I, II, and VI. Data on the number and type
of medical appointments, hospital admissions, medications used, and
surgical procedures performed per patient were obtained through a
review of medical records, as were data on ERT. These variables were
then compared between patients undergoing ERT and those not
on ERT. Results: Thirty-four patients (27 on ERT) were included inee front matter Copyright & 2015, International S
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0, 90035-003 Porto Alegre, RS, Brazil.the study. Overall, between-group differences were found in median
absolute frequencies of hospital admissions and surgical procedures
per year, both of which were higher in the non-ERT group. Further-
more, we observed a high rate of failure to record medication dosage
regimens. Conclusions: Our ﬁndings suggest that Brazilian patients
with MPS I, II, and VI who are on ERT undergo fewer medical
interventions, which can lead to a reduction in direct medical costs
to the publicly funded health care system. The cost of ERT, however, is
extremely high and probably outweighs this reduction.
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Mucopolysaccharidoses (MPSs) are a group of lysosomal storage
disorders caused by deﬁcient activity of enzymes involved in the
degradation of glycosaminoglycans (GAGs). These disorders are
characterized by intralysosomal buildup and increased urinary
excretion of GAGs, which ultimately leads to cell, tissue, and
organ dysfunction [1]. The GAG catabolism pathway involves
different enzymes; deﬁciency of each of these 11 enzymes is
associated with a speciﬁc type of MPSs [2] (see Appendix Table in
Supplemental Material found at http://dx.doi.org/10.1016/j.vhri.
2015.08.002). From a clinical standpoint, the MPS share many
features, and so enzyme assays or DNA analyses are required
for diagnostic conﬁrmation. All are progressive disorders, char-
acterized by childhood onset, and usually lead to death at anearly age; the severity of clinical presentation is extremely
variable, but predominantly comprises complications due to the
buildup of GAGs in the respiratory system (recurrent respiratory
tract infections, obstructive sleep apnea, restrictive lung disease),
heart (valve disease), and joints/bone (dysostosis multiplex,
decreased joint range of motion). Neurological involvement, is
common; mucopolysaccharidosis type IV-A (MPS IV-A) and
mucopolysaccharidosis type VI (MPS VI) were originally believed
to be “protected” from cognitive involvement, but an article
suggests that it may occur even in MPS VI [3]. Mucopolysacchar-
idosis type III-D, mucopolysaccharidosis type IV-B, mucopolysac-
charidosis type VII, and mucopolysaccharidosis type IX are the
rarest types. Mucopolysaccharidosis type I (MPS I) is the leading
type of MPSs in the United Kingdom [4], mucopolysaccharidosis
type II (MPS II) is the most common type in Brazil [5] and Japanociety for Pharmacoeconomics and Outcomes Research (ISPOR).
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According to the São Paulo State MPS Association (Associação
Paulista de MPS), as of 2012, there were 645 patients living with
MPSs in Brazil: 160 with MPS I, 191 with MPS II, 33 with MPS III, 79
with MPS IV, and 182 with MPS VI (Nilton Próspero, personal
communication, 2012). MPS II is the only form that presents an X-
linked recessive pattern of inheritance; hence, it is found almost
exclusively in male patients [6].
There is no curative treatment for MPSs. Currently available
treatment options include interventions that target the clinical
phenotype (supportive care or symptomatic therapy) and those
that target the mutant protein (speciﬁc treatments, such as
hematopoietic stem cell transplantation [HSCT] and enzyme
replacement therapy [ERT]) [8]. Growing research interest in MPSs
from a health technology assessment standpoint is explained by
the advent of ERT for MPS I, II, IV-A, and VI, a high-cost treatment
modality [8] that has been approved by regulatory agencies
within the framework of so-called orphan drugs (see Appendix
Table). Notably, no such framework exists in Brazil. ERT for MPS I
consists of intravenous administration of laronidase, a protein
analogue of human α-L-iduronidase produced from Chinese
hamster ovary (CHO) cells [9]. ERT for MPS II consists of intra-
venous administration of idursulfase, an analogue of human
iduronate-2-sulfatase produced from human cell lines [10,11],
whereas therapy for MPS VI consists of intravenous administra-
tion of galsulfase, an analogue of N-acetylgalactosamine 4-
sulfatase (arylsulfatase B) also produced from CHO cells [12,13].
ERT with recombinant human GALNS (elosulfase alfa) represents
a new treatment option for patients with MPS IVA that was
approved in the United States by the Food and Drug Adminis-
tration in February 2014. Elosulfase alfa is produced in a genet-
ically engineered CHO mutant cell line that expresses the cDNA
encoding for the full human GALNS protein [14].
The high cost of orphan drug development for the treatment
of these diseases, compounded by the difﬁculty of conducting
clinical trials in an extremely low population, shows that it can
be characterized as a public health problem [15]. The present
study constitutes the ﬁrst stage of a larger project that seeks to
estimate the economic impact of ERT for MPS I, II, and VI on the
Brazilian publicly funded health care system, the Uniﬁed Health
System (Sistema Único de Saúde [SUS]). As well as test the data
collection instrument, our objective was to evaluate the fre-
quency of medical interventions performed in Brazilian patients
with MPS I, II, and VI regularly followed up at SUS hospitals so as
to estimate the impact of ERT on direct medical resources, and to
establish whether they are related to the severity and duration of
the disease.Methods
Study Design
This was a retrospective, hospital-based, cohort study designed
to collect data on variables of interest to a pharmacoeconomic
assessment of ERT for MPS I, II, and VI. MPS IV-A was not
included because ERT with elosulfase alfa was not approved at
the time of the study. The study was approved by all involved
ethics committees.
Data Collection Instrument
The data collection instrument (available on request) consisted of
15 questions organized in two sections. The ﬁrst section was
designed to obtain general data on each patient: center of origin,
severity of phenotype (with or without cognitive involvement,
according to the registries), ERT status, history of HSCT, date ofbirth, date of diagnosis, date of ﬁrst medical geneticist appoint-
ment, date of ﬁrst infusion (in case of ERT), and date of death
(when applicable). The second section of the instrument was
designed to collect data on variables directly associated with the
cost of MPS treatment. Data recorded included the date, specialty,
and reason for each medical appointment; the date, type, and
indication for each test; the date, type, and length of stay for each
surgical procedure; the type, cause, and length of stay for each
hospital admission; and the type, dosage regimen, duration of
use, and indication for each medication prescribed. Data were
also collected on ancillary therapies, such as physical therapy,
speech and language therapy, occupational therapy, social serv-
ices, and psychology or counseling (duration, frequency, and
indication for visits), and on the use of medical devices, including
eyeglasses, hearing aids, wheelchairs, and continuous positive
airway pressure/bilevel positive airway pressure devices. For
patients on ERT, a separate data collection sheet was speciﬁcally
designed to record the date and number of infusions performed,
the number of infusions lost, the number of vials used (dose
calculated according to body weight), premedication, and infu-
sion duration. Throughout 2011, one of the investigators (F.H.B.)
reviewed the records of all the patients included in the study and
completed the data collection instrument.Sample
A convenience sampling strategy was used. Four Brazilian MPS
treatment centers were included in this study: the Medical
Genetics Service of Hospital de Clínicas de Porto Alegre, state of
Rio Grande do Sul (SGM-HCPA); the Department of Medical
Genetics of Universidade Estadual de Campinas, state of São
Paulo; Pontifícia Universidade Católica de Campinas, state of São
Paulo; and the Department of Pediatrics at Universidade Estadual
do Rio de Janeiro, state of Rio de Janeiro. These centers were
chosen because all kept high-quality patient records, all are part
of the SUS, all are afﬁliated with universities in the south or
southeast regions of Brazil, and all monitored both patients who
were on ERT and those not on ERT (the exceptions were Depart-
ment of Medical Genetics of Universidade Estadual de Campinas,
state of São Paulo, which followed patients not on ERT, and
Pontifícia Universidade Católica de Campinas, state of São Paulo,
which monitored only those on ERT). Furthermore, all are led by
medical geneticists. This would ensure good record-keeping and
a measure of consistency with respect to follow-up protocols. It
bears noting that of the four participating centers, only one (SGM-
HCPA) had electronic medical records.Patient Inclusion/Exclusion Criteria
The patient inclusion criteria were as follows:1. Diagnosis of MPS I, II, or VI conﬁrmed by enzyme assay in
plasma/leukocytes or ﬁbroblasts and/or DNA analysis;2. Not being on a clinical trial involving ERT;
3. No history of HSCT;
4. Treatment duration, according to presence or absence of ERT:
a. Patients in the ERT group were required to undergo regular
follow-up and to be on ERT for at least 12 months before
the start of data collection (January 2011).
b. Patients in the no ERT group were required to undergo
regular follow-up for at least 12 months before the start of
data collection (January 2011).For purposes of analysis, patients aged 18 years or older were
considered adults. All others were classiﬁed as children/
adolescents.
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Method
The data collection instrument was designed by the multid-
sciplinary team of study investigators, which comprises physi-
cians, pharmacists, health technology assessment experts, and
economists.
The data collection allowed the evaluation of the study
instrument regarding its layout. The quality of data records was
appraised qualitatively and quantitatively by analysis of the
number of missing variables in the instrument (due to missing
data or inadequate record-keeping) and of the quality of infor-
mation obtained. For the variables medical appointments, tests,
hospital admissions, and surgical procedures, records were con-
sidered adequate if they contained information on the type of
intervention, the date of intervention, the duration or frequency
of the intervention, and the indication(s) for the intervention.
Records were considered adequate for ancillary therapies if they
contained information on the type, frequency, and duration of
therapy; for medications (pharmacotherapy), if they contained
data on the active pharmaceutical ingredients used, duration,
dosage regimen, and indications for each medication; for
chronic-use medical devices, if they contained information on
the date use of each device was started; and ﬁnally, regarding
ERT, records were considered adequate if they contained data on
time on ERT, number of vials used, number of scheduled
infusions, and number of completed infusions.Estimation of the Effect of ERT, Cognitive Involvement, and
Duration of the Disease on the Frequency of Medical
Interventions
All data were collected by a chart review.
The following data were taken into account for this analysis:
date of birth, age at diagnosis, presence of cognitive involvement
(according to medical records, even in the absence of IQ testing),
date ERT was started, and frequency of medical interventions
(number and type of hospital admissions, tests, surgical proce-
dures, medical appointments, and medications prescribed/used)
performed between January and December 2010.
Medications used as part of ERT (laronidase, idursulfase, or
galsulfase, premedications and medications used in the treat-
ment of infusion adverse reactions) and those not directly related
to MPS management (such as oral contraceptives) were not
tallied. For the purposes of this study, the number of medications
used was deﬁned as the number of different active pharmaceut-
ical ingredients used during the study period; for example, if a
patient received two courses of plain amoxicillin and one course
of amoxicillin/clavulanate, these would be tallied as “two med-
ications used during the study period.”
Tests were tallied as a single instance when performed on the
same day; for example, complete blood cell count alone or
complete blood cell count plus platelet count were both counted
as a single test for statistical purposes as long as both tests were
performed at a single visit. This practice was used for hematology
and biochemistry tests alike, including urea, creatinine, bilirubin,
Alanine transaminase (ALT), aspartate transaminase (AST),
Gamma-glutamyl transferase (GGT), lactate dehydrogenase
(LDH), alkaline phosphatase, cholesterol, glucose, sodium, potas-
sium, chloride, magnesium, calcium, phosphorus, albumin, glob-
ulins, and total protein. Conversely, imaging tests of different
body segments were counted separately even when performed
on the same day.
Variables (medians) were initially assessed with regard to
disease duration (equivalent to the age of the patient; in this
analysis, data only from patients in the non-ERT group were
taken into account) and presence/absence of cognitiveinvolvement. To assess the inﬂuence of time on ERT on the
variables of interest, data from the ERT group were included.Statistical Analysis
Databases were constructed in Microsoft Ofﬁce Excel 2010, and
statistical analyses were performed in the SPSS 20.0 software
environment. Descriptive data were described as frequencies,
means and SDs, and medians and quartiles.
For evaluating the effect of the duration of disease on the
frequency of medical intervention, a Pearson correlation was
performed. The inﬂuence of the presence of cognitive involve-
ment on other variables was then assessed using the Kruskal-
Wallis test. The Mann-Whitney U test was used for comparison of
the median number of medications, medical appointments,
hospital admissions, tests, and surgical procedures in the ERT
and non-ERT groups. To assess the inﬂuence of time on ERT on
the variables of interest, data from the ERT group were included
and Pearson correlation coefﬁcients were calculated.
For all analyses, P values of less than 0.05 were considered
statistically signiﬁcant.
All monetary values that are expressed in pounds sterling
were obtained through the exchange rate provided by the Central
Bank of Brazil (Banco Central do Brasil) on July 15, 2014. Because
the data collected are prior to 2010, the monetary values deter-
mined may have suffered variations because of annual inﬂation
rates in Brazil (around 6%).Results
Forty-three patients with MPSs (I ¼ 15, II ¼ 23, VI ¼ 5) were alive
and registered at the four participating centers in 2010. Of these,
only 35 met the inclusion criteria because 8 did not have any
appointments in 2010 (e.g., they were not regularly seen at the
center). The medical records of one patient were not available for
review. Therefore, the sample comprised 34 patients: 27 on ERT
(“ERT group”) and 7 receiving supportive care only (“non-ERT
group”). The reasons why patients from the non-ERT group were
not receiving ERT were not clearly stated in medical records.
Table 1 describes the proﬁle of the patients included in the sample.Appraisal of the Data Collection Instrument
Table 2 lists the variables associated with the cost of MPS
treatment and describes our appraisal of the adequacy of
record-keeping of these variables in patient charts.
Data on the chronic use of medical devices and information
on ancillary therapies are presented in Table 3.Inﬂuence of Disease Duration on the Variables of Interest
There were no signiﬁcant correlations between length of disease
and any of the variables of interest (data not shown).Comparison between the ERT and Non-ERT Groups
There were signiﬁcant between-group differences in the median
number of hospital admissions and surgical procedures, both of
which were higher in the non-ERT group (Table 4).
There were no signiﬁcant between-group differences when
only children and adolescents were taken into account (data not
shown). Because there were no patients older than 18 years in the
non-ERT group, no such analysis could be conducted for adult
patients.
Table 1 – Proﬁle of Brazilian MPS I, II, and VI
patients included in the sample.
Patients proﬁle No ERT
(n ¼ 7)
ERT
(n ¼ 27)
MPS type
I 1 11
II 5 12
VI 1 4
Sex
Female-to-male ratio (n) 2:5 8:19
Center of origin
HCPA 6 17
Other participating centers 1 10
Median age at diagnosis (y)
(IQR 25–75)
2.2 (1.6–5.8) 6.2 (6.8–12.3)
Median time elapsed
between diagnosis and
study enrollment (y) (IQR
25–75)
4.5 (3.9–5.7) 9.4 (9.6–12.2)
Age at study enrollment (y),
n (%)
Children/adolescents
(o18y)
7 (100) 16 (59.2)
Adults (Z18y) 0 11 (40.8)
Median (IQR 25–75) 6.8 (4.8–9.4) 12.8 (9.4–22.6)
Cognitive involvement
Present, n (%) 6 (85.7) 9 (33.3)
MPS I 1 4
MPS II 4 5
MPSVI 1 0
Median age at ERT onset (y)
(IQR 25–75)
10.5 (7.7–19.0)
MPS I – 17.8 (14.8–25.3)
MPS II – 10.1 (7.3–17.2)
MPS VI – 9.8 (8.7–10.6)
Median time on ERT (y) (IQR
25–75)
– 2.7 (1.56–5.3)
MPS I 3.7 (2.3–5.8)
MPS II 2.6 (1.2–3.8)
MPS VI 3.2 (2.6–4.1)
Scheduled infusions per year – 48
Median infusions
performed (IQR 25–75)
– 46 (45–47)
ERT, enzyme replacement therapy; HCPA, Hospital de Clínicas de
Porto Alegre; IQR, interquartile range; MPS I, mucopolysacchari-
dosis type I; MPS II, mucopolysaccharidosis type II; MPS VI,
mucopolysaccharidosis type VI.
Table 2 – Adequacy of medical record information in
relation to variables analyzed in the present study.
Variable No. of patients
with
intervention
reported in
medical records
No. (%) of
patients
with
adequate
records*
Medical appointments 33
Date 33 (100)
Type 33 (100)
Indication 17 (51.5)
Hospital admissions 12
Length of stay 11 (91.7)
Indication 12 (100)
Surgical procedures 6
Date 5 (83.3)
Type 6 (100)
Length of stay 6 (100)
Tests 32
Date 32 (100)
Type 32 (100)
Indication 15 (46.9)
Medications 19
Type 19 (100)
Dosage regimen 7 (36.8)
Indications for use 7 (36.8)
Duration of use 18 (94.7)
ERT 27
Number of vials used 27 (100)
Number of
scheduled and
missed infusions
27 (100)
ERT, enzyme replacement therapy.
* Adequate record-keeping was deﬁned as the presence of
information pertaining to the variables listed in the leftmost
column of the table in the medical records of each patient.
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Comparison between patients with cognitive involvement and
those with no cognitive involvement showed that the former
used a signiﬁcantly greater number of medications, both in the
ERT (P ¼ 0.032) and in the non-ERT (P ¼ 0.024) groups.
Inﬂuence of Time on ERT on the Variables of Interest
A correlation was found between time on ERT and the median
number of hospital admissions (r ¼ –0.504; P ¼ 0.007). Time on
ERT did not correlate with any other variables (data not shown).
When only patients younger than 18 years were considered,
there was also a correlation between time on ERT and the median
number of hospital admissions (r ¼ –0.674; P ¼ 0.004). No such
correlation was found in adult patients.Discussion
The importance of this article is based on the worldwide scientiﬁc,
economic, and social relevance of rare diseases and orphan drugs.
The present study used an exploratory and retrospective
design and was based exclusively on data contained in patient
records before the implementation of Ordinance No. 199, January
30, 2014, from the Brazilian Ministry of Health, which establishes
the National Policy on Comprehensive Care for People with Rare
Diseases in the SUS. The policy forecasts the incorporation and
use of technologies for the promotion, prevention, and compre-
hensive care, including drugs and nutritional formulas as speci-
ﬁed in the SUS, which will change the panorama of rare diseases
in the county. For purposes of this ordinance, a disease that
affects up to 65 people in every 100,000 individuals, or 1.3 people
per 2000 individuals [16], is considered a rare disease.
Unfortunately, most participating centers did not have electronic
medical records. Furthermore, some centers use different records or
forms for different departments or sectors in which patients are
seen over the course of their treatment, thus making data collection
a complex, extensive, and eventually incomplete endeavor.
However, one of the advantages of chart review studies is that
medical records provide very precise information on the date and
type of medical appointments, surgical procedures, hospital admis-
sions, and tests performed at the hospital in which patients receive
follow-up, as well as the type and duration of pharmacotherapy.
Table 3 – Adequacy of medical record information in
relation to the use of medical devices and ancillary
therapies by Brazilian patients with MPS I, II, and
VI.
Medical devices/
Ancillary
therapies
No. (%) of patients
with intervention
reported in
medical records
No. (%) of
patients with
adequate
records*
Medical devices for
long-term use
16†/34 (47.0) 13/16 (81.2)
Eyeglasses 6 5
Hearing aid 5 3
CPAP 3 2
BiPAP 1 0
Walker 1 1
Wheelchair 1 0
Leg orthosis 1 1
Neck brace 1 1
Ancillary therapies 15‡/34(44.1) 9/34 (60)
Physical therapy 10 4
Speech-language
pathology
4 1
Occupational
therapy
0 0
Social services 4 4
Psychologist/
counselor
0 0
BiPAP, bilevel positive airway pressure; CPAP, continuous positive
airway pressure; MPS I, mucopolysaccharidosis type I; MPS II,
mucopolysaccharidosis type II; MPS VI, mucopolysaccharidosis
type VI.
* Adequate record-keeping was deﬁned as the presence of
information pertaining to the type of device and date device
use began (for medical devices) or duration, frequency, and type
of therapy (for ancillary therapies).
† Three patients used more than one device.
‡ Three patients were undergoing more than one type of therapy.
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ancillary therapies apparently were not adequately recorded.
In 2012, Wyatt et al. [17] conducted a pioneering study of the
costs of MPS I and MPS II treatment in the United Kingdom. All
cost estimates in their investigation were based on data collected
by means of questionnaires designed to obtain information on
the last 12 months of patient follow-up. Questionnaires were
administered directly to patients whenever possible or to their
caregivers otherwise. One of the advantages of this mode of data
collection is that patients and their caregivers are more likely to
have reliable information on ancillary therapies, such as physical
therapy, speech and language pathology, and occupational ther-
apy, as well as on the duration of use of medical devices.
Therefore, we suggest that future studies on this topic use both
designs and data collection methods, so as to ensure collection of
reliable data.
We detected a high rate of missing data in relation to the
reasons or indications for medical appointments and tests.
Although this circumstance hinders assessment of the natural
history of MPS, it has little impact on pharmacoeconomic anal-
ysis of the treatment of MPS. Missing data pertaining to medi-
cation dosage regimens, however, will certainly affect the
calculation of MPS treatment costs in subsequent stages of our
project. Another point worth considering concerns collection of
data on chronic use of medical devices and use of ancillary
therapies, as mentioned above. In addition to the issue ofinadequate record-keeping, we found that very few patients
actually used these interventions—fewer than expected. Children
with severe MPS I, for instance, have limited development of
language skills [1] and monitoring by a speech-language pathol-
ogist is essential. From a behavioral standpoint, children with
MPS I tend to be placid, whereas those with MPS II tend to exhibit
aggressive behavior [1]; therefore, psychological treatment can
play a very important role. Hearing loss is quite common in MPS
[1], and many patients require hearing aids. Obviously, the low
rate of use of these services and devices in our sample may be
secondary to failure to record these interventions in patient
charts, or may reﬂect difﬁculty obtaining access to these thera-
pies. Brazilian MPS treatment centers do not always make
ancillary therapies available to all patients; when provided, they
are often extramural, which may explain, at least partly, why
their use was not reported in patient records. Previous studies by
our group [19,20] suggest, however, that many patients with MPS
actually did not have access to ancillary therapies. Turra and
Schwartz [18] conducted a multicenter study including 78 Brazil-
ian patients with MPS (17 presenting with mental retardation)
who underwent an interview with a speech and language
therapist and physical examination. Of these patients, only 18
were undergoing speech therapy intervention at the time of the
study [18]. In 2012, Guarany et al. [19] conducted a prospective,
longitudinal study of 21 Brazilian patients with MPSs. Of these,
only seven reported that they have been treated at rehabilitation
clinics or institutions; physical therapy, speech therapy, and
psychotherapy were among the treatments provided.
Despite missing data, the study instrument was able to collect
reliable records on the frequency and type of medical interven-
tions in this patient sample, thus providing data for future
analysis of the treatment costs of MPS I, MPS II, and MPS VI.
Descriptive Analysis of Treatment Costs in MPS I, II, and VI
Since its establishment in 1990, the SUS has ensured the right to
care—including medical appointments, tests, hospital admission,
and treatment—at all afﬁliated health facilities to all Brazilian
citizens [20]. Nevertheless, the demand for ERT is on the rise,
with patient requests many times supported by court orders that
conﬂict directly with Brazil’s National Medicines Policy and with
evidence-based medicine. Furthermore, the inﬂuence of pharma-
ceutical industry lobbying for registration and marketing of new
drugs in Brazil cannot be ruled out [21]. A Brazilian article
published in 2012 showed that in the case of MPSs, litigation
results from the lack of a clear policy in the health system for rare
diseases in general, thereby leading to excessive expenditures for
MPS treatment. The authors reviewed ﬁles from 196 court rulings
ordering the Brazilian Ministry of Health to provide medicines, in
addition to Ministry of Health administrative records. Overall, 195
patients sued to secure their access to laronidase, idursulfase,
and galsulfase between 2006 and 2010, at a total cost of
£57,112,763.76 to the public purse, distributed as follows:
£2,408,375.06 for laronidase (24 patients with MPS I),
£22,616,218.82 for idursulfase (68 patients with MPS II), and
£32,088,170.14 for galsulfase (103 patients with MPS VI) [15].
Despite the high cost of recombinant enzymes for the treat-
ment of MPS I, II, and VI, the current state of the evidence
provides only limited information on the overall cost burden of
these conditions [15]. Within this context, the present study was
the ﬁrst Latin American investigation to assess the economic
impact of ERT on the cost burden of disease as represented by
medical interventions.
The only similar study in the international literature is the
aforementioned investigation by Wyatt et al. [17], which con-
sisted of a retrospective assessment of 68 patients with MPS I (20
adults and 48 children) and 39 patients with MPS II (3 adults and
Table 4 – Comparison between the ERT and non-ERT groups.
Medical interventions No ERT (n ¼ 7) ERT (n ¼ 27) P
Medical appointments
Number/patient, median (IQR 25–75) 8 (2–13) 7 (3–10) 0.915
Patients who attended visits in the
period, n (%)
7 (100) 26 (96.2)
Most commonly seen specialists* Ear-nose-throat, medical geneticists,
surgeons
Geneticists, ear-nose-throat,
pulmonologists
Hospital admissions
Number/patient, median (IQR 25–75) 1 (0–2) 0 (0–1) 0.015
Patients who were hospitalized in
the period, n (%)
5 (71) 7 (25.9)
Most common reasons for hospital
admission*
Asthma, respiratory insufﬁciency Respiratory insufﬁciency,
surgery
Surgeries
Number/patient, median (IQR 25–75) 0 (0–2) 0 (0–0) 0.040
Patients who underwent surgery in
the period, n (%)
3 (42.8) 3 (11.1)
Most commonly performed
surgeries*
Adenoidectomy, umbilical hernia
repair, tonsillectomy
Adenoidectomy, inguinal hernia
repair, myringotomy
Tests
Number/patient, median (IQR 25–75) 13 (6–44) 8 (2–13) 0.096
Patients who had tests in the period,
n (%)
7 (100) 25 (92.5)
Most commonly performed tests* Blood counts/chemistry panels, chest
X-ray, echocardiogram
Blood counts/chemistry panels,
urinary GAG measurement,
echocardiogram
Medications†
Number/patient, median (IQR 25–75) 2 (0–22) 3 (0–3) 0.735
Patients who used medications in
the period, n (%)
4 (57–1) 15 (55.5)
Most commolnly prescribed
medications*
Antibiotics, analgesics, corticosteroids Analgesics, antibiotics,
antihistamines
ERT, enzyme replacement therapy; GAG, glycosaminoglycan; IQR, interquartile range.
 Listed in order of frequency.
† Median refers to the number of different active pharmaceutical ingredients used during the study period.
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group, 24 patients with no cognitive involvement (12 children and
12 adults) were on ERT, with a median time on ERT of 4.68 years,
slightly higher than that found in our sample. The remaining
patients in the Wyatt et al. [17] sample had undergone HSCT,
whereas the other patient with MPS I in our sample was on
supportive care alone. Wyatt et al. [18] estimated the annual cost
of MPS I treatment to the National Health Service (NHS) and
publicly funded social-care services, including the costs of hos-
pital services (hospital admissions, medical appointments, etc.)
and extramural services (occupational therapy and other thera-
pies) at £2000 for adult patients and £5300 for children. Further-
more, the annual cost of laronidase ERT was estimated as
£258,201 for an adult patient versus £139,563 for a child. Thirty-
seven patients with MPS II were on ERT, with a median time on
ERT similar to that found in our sample. The two other patients
with MPS II included in the sample were receiving supportive
care alone [17]. Wyatt et al. [17] estimated the annual cost to the
NHS and publicly funded social-care services at £15,500 for an
adult patient with MPS II and £3500 for a child with MPS II. The
annual cost of idursulfase ERT was £537,605 for an adult patient
versus £314,004 for a child with the condition.
In the Wyatt et al. [17] sample, median age at ERT onset was
18.7 years for adults and 3.38 years for children with MPS I and16.6 years for adults and 6.96 years for children with MPS II. In our
sample, onset of ERT was later in both forms of MPSs, and in
children and adults alike (data not shown). Many factors may
have contributed to this late onset of therapy, including delays in
diagnosis and the lack of reimbursement of ERT in Brazil. A study
of 113 Brazilian patients with several forms of MPSs showed a 4.8-
year delay between symptom onset and diagnostic conﬁrmation
[22]. Because of the progressive course of MPSs, early diagnosis
and immediate institution of therapy are paramount [23], and
may even lead to a reduction in treatment costs. Case studies of
nontwin siblings with MPS I, II, and VI have reported much better
outcomes in siblings who are diagnosed at birth and begin ERT
within the ﬁrst 6 months of life [24–26].
When analysis was restricted to children and adolescents, we
found no difference between the ERT and non-ERT groups in terms
of the frequency of medical interventions. These results are in line
with those of Wyatt et al. [17], who found that in children with MPS I,
there was no association between time on ERT and total NHS and
social-care costs, hospital-care costs, or non–hospital-care costs, and
in children with MPS II, there was no statistically signiﬁcant
association between time on ERT and total NHS and social-care
costs or non–hospital-care costs. The authors, however, did ﬁnd an
association between time on ERT and hospital costs (hospital
admissions, accident, and emergency visits, etc.) (costs 3.78 times
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taken into account is the difference in proﬁle between the two
groups of the present study: the non-ERT group was composed
exclusively of children and adolescents, most with MPS II, whereas
only 59.3% of the patients in the ERT group were children. Contrary
to the suggestion by Wyatt et al. [17] that children with MPS II
generate a lower cost burden than do adults, our data suggest higher
costs for patients not on ERT; consequently, the higher cost burden
of this group must be attributable to children and adolescents.
Analysis of all patients regardless of age showed that the
frequency of medical interventions was essentially similar in the
ERT and non-ERT groups, with the exception of surgical proce-
dures and hospital admissions, which were less frequent in the
ERT group. In our sample, the leading causes of hospitalization in
both groups were respiratory tract infections and surgery.
According to the SUS coding database, Sistema de Gerenciamento
da Tabela de Procedimentos, Medicamentos e Órteses e Próteses
e Materiais do Sistema Único de Saúde (SIGTAP), the total cost
(including hospital charges and provider fees) of an adenoidec-
tomy, bilateral inguinal hernia repair, or umbilical hernia repair—
the most common surgical procedures in both groups—is £90.53,
£90.01, and £93.77, respectively [27]. Despite the cost of ERT, the
impact of these costs appears to be lower in the ERT group, due to
the relatively low frequency of surgical procedures and hospital
admissions. According to SIGTAP, the cost of 1 day in an
intensive care unit (adult or pediatric) is £36.14 [27].
Our ﬁndings also suggest that the most common medical
procedures in both groups are physician appointments (medical
appointments) and tests. Within the SUS, according to SIGTAP
[27], the reimbursement rate for a visit to a primary care
physician (e.g., to a pediatrician or general surgeon) is £0.53,
whereas the rate for a specialist physician visit (e.g., geneticist or
cardiologist) is £2.60. Since the creation of Ordinance No. 199,
SIGTAP began to incorporate the procedure of Clinical Diagnostic
Evaluation for Rare Disorders – Inborn Errors of Metabolism with
a total cost of £156.00. Among the list of inborn errors of
metabolism contemplated by this assessment, there are MPS I
and MPS II. MPS VI, in turn, does not ﬁt in this procedure [27].
Therefore, we believe that the costs of physician appointments
will not be a major burden on the total treatment costs of
patients with MPS I, II, or VI. This ﬁnding is consistent with the
results reported by Wyatt et al. [17].
The most common tests undergone by patients included com-
plete blood cell counts/blood chemistry panels, chest radiographs,
echocardiography, and urinary GAG quantitation. The SUS covers the
costs associated with these interventions, with a reimbursement rate
of £1.07 per sample for complete blood cell counts, £0.48 to £0.91 for
each blood chemistry test (urea, creatinine, bilirubin, Alanine trans-
aminase (ALT), aspartate transaminase (AST), Gamma-glutamyl
transferase (GGT), lactate dehydrogenase (LDH), alkaline phospha-
tase, cholesterol, glucose, sodium, potassium, chloride, magnesium,
calcium, phosphorus, albumin, globulins, and total protein), £1.79 per
plain chest radiograph, and £10.38 for echocardiography [27]. We
observed an increase in the frequency of urinary GAG quantitation
orders in the ERT group. This is attributable to three factors. First,
urinary GAG levels are used extensively in clinical trials of ERT for
MPS I, II, and VI as a pharmacodynamic marker of in vivo enzyme
activity and a purported surrogate biomarker of treatment response
[28]. Second, because ERT is a novel treatment modality and has
been the subject of relatively little study, attending physicians are
understandably concerned about its effects; this leads to an increase
in test orders. Third, according to the protocol for follow-up of
patients with MPS I, II, and VI developed by Rede MPS Brasil (a
network of Brazilian medical genetics services supported by public
and private funding), GAG quantitation should be performed every 3
months [5]. Although currently the identiﬁcation of urinary GAGs, as
well as enzymatic assays in plasma and leukocytes for the diagnosisof EIM, is still to be covered by the SUS [27] at the time of conducting
the study, urinary GAG quantitation was available only through the
SUS for diagnostic purposes, with a reimbursement list rate of £0.96
per sample. In addition to not listing which assays are included in
this test (toluidine blue, GAG chromatography or electrophoresis, or
GAG quantiﬁcation), it does not cover any form of GAG quantitation
for monitoring purposes [27]. Therefore, at all participating centers,
all GAG quantitation tests performed during the pre-ERT period (for
diagnostic purposes) and during ERT are covered by MPS Brazil
Network.
Thus far, no studies have been published on the cost of
galsulfase ERT in patients with MPS VI. Although the worldwide
incidence of MPS VI is estimated at only 1:250,000 live births [29], it
seems to be more common in Brazil. A study conducted in the
southern region of the country found a high frequency of MPSs
among inborn errors of metabolism, with MPS I and MPS VI being
the most frequently diagnosed forms [30]. Monte Santo, a munic-
ipality in northeastern Brazil, features a markedly elevated inci-
dence of several genetic conditions, including MPS VI. The
incidence of MPS VI in the area is estimated at 1 in 5000 live births
[31]. Within this context, it needs to be noted that this was the ﬁrst
study to address the pharmacoeconomics of ERT for MPS VI.
A previous study conducted by our group assessed the effects
of ERT in a sample of patients with MPS I (n ¼ 9) throughout their
follow-up at SGM-HCPA. Variables were compared between the
pre-ERT and post-ERT periods within the same group of patients.
Our ﬁndings suggested that ERT does not alter the natural history
of MPS I (according to the medical interventions analyzed), and
that—contrary to the ﬁndings of the present study—the treatment
costs of patients with MPS I increase during ERT. Comparison
between these two retrospective, hospital-based studies clearly
shows the superior design and larger sample size of the present
investigation [32]. Furthermore, the previous study was restricted
to patients with MPS I, whereas the present study included
patients with MPS II and MPS VI as well. In view of the sample
size, we chose not to conduct subgroup analyses by MPSs type.
Hence, there may be differences in terms of cost and treatment
efﬁcacy among patients with each of these three types of MPSs.Conclusions
Our ﬁndings suggest that excluding the cost of recombinant
enzymes, Brazilian patients with MPS I, II, and VI who receive
disease-speciﬁc treatment undergo fewer medical interventions
than do patients in supportive care. This seems to be associated
with lower SUS expenditures with direct medical costs for
patients with ERT. Despite some missing data, particularly
regarding medication dosage and administration regimens, the
study instrument appears adequate for collection of data on the
costs associated with treatment of MPSs. Longitudinal studies
will be useful in the evaluation of the long-term costs associated
with ERT and its impact on the SUS.Acknowledgments
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